- Home
- CRBP vs QUIK Comparison
CRBP vs QUIK Comparison
Compare CRBP & QUIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- QUIK
- Stock Information
- Founded
- CRBP 2009
- QUIK 1988
- Country
- CRBP United States
- QUIK United States
- Employees
- CRBP N/A
- QUIK N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- QUIK Semiconductors
- Sector
- CRBP Health Care
- QUIK Technology
- Exchange
- CRBP Nasdaq
- QUIK Nasdaq
- Market Cap
- CRBP 114.8M
- QUIK 100.1M
- IPO Year
- CRBP N/A
- QUIK 1997
- Fundamental
- Price
- CRBP $16.22
- QUIK $6.93
- Analyst Decision
- CRBP Strong Buy
- QUIK Strong Buy
- Analyst Count
- CRBP 8
- QUIK 3
- Target Price
- CRBP $50.57
- QUIK $10.87
- AVG Volume (30 Days)
- CRBP 221.8K
- QUIK 207.6K
- Earning Date
- CRBP 11-06-2025
- QUIK 11-10-2025
- Dividend Yield
- CRBP N/A
- QUIK N/A
- EPS Growth
- CRBP N/A
- QUIK N/A
- EPS
- CRBP N/A
- QUIK N/A
- Revenue
- CRBP N/A
- QUIK $18,359,000.00
- Revenue This Year
- CRBP N/A
- QUIK N/A
- Revenue Next Year
- CRBP $220.00
- QUIK $77.05
- P/E Ratio
- CRBP N/A
- QUIK N/A
- Revenue Growth
- CRBP N/A
- QUIK N/A
- 52 Week Low
- CRBP $4.64
- QUIK $4.26
- 52 Week High
- CRBP $20.77
- QUIK $13.36
- Technical
- Relative Strength Index (RSI)
- CRBP 76.29
- QUIK 65.14
- Support Level
- CRBP $15.00
- QUIK $6.08
- Resistance Level
- CRBP $16.97
- QUIK $6.74
- Average True Range (ATR)
- CRBP 1.01
- QUIK 0.40
- MACD
- CRBP 0.28
- QUIK 0.07
- Stochastic Oscillator
- CRBP 88.62
- QUIK 86.27
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.